Literature DB >> 7196930

Altered idiotype response to phosphocholine in mice bearing an x-linked immune defect.

J J Kenny, G Guelde, J L Claflin, I Scher.   

Abstract

The x-linked CBA/N defect results in an altered idiotype expression among the anti-phosphocholine (PC) antibodies produced after antigenic challenge with the thymic dependent antigen PC-KLH but does not preclude the response to this hapten as previously suggested. The majority of immune-defective F1 male mice can be divided into 2 groups based on their T15 idiotype profile. Group 1 mice fail to produce anti-PC antibodies bearing the T15 idiotype in either a primary or secondary response, whereas group 2 mice produce low levels of T15 idiotype; however, this idiotype often appears only after secondary immunization. These responses are distinct from the anti-PC response of normal F1 females, which is predominantly of the T15 idiotype. In addition to the altered idiotype expression, F1 male mice exhibited a greatly reduced primary anti-PC response compared to normal mice, and secondary responses were approximately one-third that of normal mice. The delayed expression of anti-PC antibodies in immune defective mice appears to be due to their inability to produce IgM anti-PC antibodies in either a primary or secondary response to PC-KLH.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7196930

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Biological mimicry of antigenic stimulation: analysis of the in vivo antibody responses induced by monoclonal anti-idiotypic antibodies.

Authors:  J Y Huang; R E Ward; H Kohler
Journal:  Immunology       Date:  1988-01       Impact factor: 7.397

2.  Ultrastructural colocalization of phosphorylcholine and a phosphorylcholine-associated epitope in first-stage larvae of Trichinella spiralis.

Authors:  S Hernández; F Romarís; I Acosta; P N Gutiérrez; F M Ubeira
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

3.  Subpopulations of B cells distinguished by cell surface expression of Ia antigens. Correlation of Ia and idiotype during activation by cloned Ia-restricted T cells.

Authors:  K Bottomly; B Jones; J Kaye; F Jones
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

4.  Immune response to a thymus-dependent form of B512 dextran requires the presence of Lyb-5+ lymphocytes.

Authors:  K E Stein; D A Zopf; C B Miller; B M Johnson; P K Mongini; A Ahmed; W E Paul
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

5.  Antibody response of immunodeficient (xid) CBA/N mice to Escherichia coli 0113 lipopolysaccharide, a thymus-independent antigen.

Authors:  J R Hiernaux; J M Jones; J A Rudbach; F Rollwagen; P J Baker
Journal:  J Exp Med       Date:  1983-04-01       Impact factor: 14.307

6.  Selection of antigen-specific, idiotype-positive B cells in transgenic mice expressing a rearranged M167-mu heavy chain gene.

Authors:  J J Kenny; C O'Connell; D G Sieckmann; R T Fischer; D L Longo
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

7.  Antigen binding and idiotype analysis of antibodies obtained after electroporation of heavy and light chain genes encoding phosphocholine-specific antibodies: a model for T15-idiotype dominance.

Authors:  J J Kenny; C M Moratz; G Guelde; C D O'Connell; J George; C Dell; S J Penner; J S Weber; J Berry; J L Claflin
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

8.  Mice with the xid defect have helper cells for T15 idiotype-dominant anti-phosphorylcholine primary and secondary plaque-forming cells responses.

Authors:  J Quintáns; Z S Quan; M A Arias
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

9.  Idiotype profile of an immune response. II. Reversal of the relative dominance of major and minor cross-reactive idiotypes in arsonate-specific T-independent responses.

Authors:  J D Conger; E Lamoyi; G K Lewis; A Nisonoff; J W Goodman
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.